Daniel J Starks bought $927K of Abbott Laboratories (ABT)
Executed Apr 27, disclosed Apr 28, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Apr 28), the stock returned -8.7% (delay-adjusted); from the execution session (Apr 27), -5.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Daniel J Starks (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Abbott Laboratories (ABT). Across 2 priced purchase filings, the average 21-session return was -1.9% from execution and -3.2% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of ABT (10,000 sh across 2 lots, as filed), executed Feb 4.
Healthcare · Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→10,000 sh across 2 lots
Exec Feb 4
Filed Feb 6 · 8:04 AM ET